64.19
前日終値:
$63.26
開ける:
$63.95
24時間の取引高:
16,429
Relative Volume:
0.01
時価総額:
$4.44B
収益:
$35.93M
当期純損益:
$-244.56M
株価収益率:
-16.25
EPS:
-3.95
ネットキャッシュフロー:
$-157.31M
1週間 パフォーマンス:
+13.60%
1か月 パフォーマンス:
+21.71%
6か月 パフォーマンス:
+56.14%
1年 パフォーマンス:
+15.62%
Merus N V Stock (MRUS) Company Profile
MRUS を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
MRUS
Merus N V
|
64.20 | 4.10B | 35.93M | -244.56M | -157.31M | -3.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
476.36 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.80 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.40 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
569.92 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
295.47 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Merus N V Stock (MRUS) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-13 | 開始されました | Piper Sandler | Overweight |
2025-02-07 | 開始されました | Wells Fargo | Overweight |
2024-11-21 | 開始されました | Goldman | Buy |
2024-10-24 | 開始されました | UBS | Buy |
2024-03-28 | 開始されました | Truist | Buy |
2024-03-04 | 繰り返されました | Needham | Buy |
2023-11-02 | 開始されました | Canaccord Genuity | Buy |
2023-08-21 | 開始されました | TD Cowen | Outperform |
2022-08-02 | 開始されました | Stifel | Buy |
2022-02-11 | 開始されました | BMO Capital Markets | Outperform |
2022-02-10 | 開始されました | Needham | Buy |
2021-11-17 | 再開されました | Guggenheim | Buy |
2021-06-07 | アップグレード | Citigroup | Neutral → Buy |
2021-04-08 | 開始されました | William Blair | Outperform |
2021-03-16 | 開始されました | SVB Leerink | Outperform |
2020-06-26 | 開始されました | H.C. Wainwright | Buy |
2020-05-27 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2019-11-20 | 再開されました | Guggenheim | Buy |
2019-06-28 | 開始されました | ROTH Capital | Buy |
2019-04-12 | 再開されました | Guggenheim | Buy |
2019-04-03 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
2019-03-27 | 開始されました | Berenberg | Buy |
2018-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
2017-03-21 | ダウングレード | Citigroup | Buy → Neutral |
2016-12-22 | アップグレード | Citigroup | Neutral → Buy |
2016-11-07 | ダウングレード | Citigroup | Buy → Neutral |
2016-06-13 | 開始されました | Citigroup | Buy |
2016-06-13 | 開始されました | Guggenheim | Buy |
2016-06-13 | 開始されました | Wedbush | Outperform |
すべてを表示
Merus N V (MRUS) 最新ニュース
What analysts say about Merus N.V. stockMarket-leading profit generation - Autocar Professional
Merus N.V. Stock Analysis and ForecastPowerful market insights - jammulinksnews.com
What drives Merus N.V. stock pricePhenomenal trading returns - Autocar Professional
Is Merus N.V. a good long term investmentRapidly expanding wealth - Autocar Professional
Merus Shares Soar 3.24% On Positive Cancer Study Update - AInvest
Merus NV stock hits all-time high, reaching 62.98 USD - Investing.com
Merus Shares Surge Amid Promising Cancer Study - TipRanks
Merus N.V. Advances in Head and Neck Cancer Treatment with Phase 3 Study - TipRanks
Learn to Evaluate (MRUS) using the Charts - news.stocktradersdaily.com
Merus N.V. (NASDAQ:MRUS) Shares Sold by Teacher Retirement System of Texas - Defense World
Merus N.V. (NASDAQ:MRUS) Given Average Rating of “Buy” by Analysts - Defense World
Why Merus N.V. stock attracts strong analyst attentionFree Access to Community - Newser
How Merus N.V. stock performs during market volatilitySwing Trade Signals - newser.com
Merus (MRUS) Gets a Buy from H.C. Wainwright - The Globe and Mail
What makes Merus N.V. stock price move sharplyAlpha Stock Ideas - Newser
Insider Selling: Merus N.V. (NASDAQ:MRUS) COO Sells $924,275.00 in Stock - Defense World
Merus (NASDAQ:MRUS) Upgraded by Wall Street Zen to Hold Rating - Defense World
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success - sharewise.com
Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III - Insider Monkey
Merus N.V.: Making Progress (NASDAQ:MRUS) - Seeking Alpha
Merus N.V.’s Promising Phase 3 Study in Head and Neck Cancer: What Investors Need to Know - TipRanks
Merus gains after mid-stage trial data for lead asset in head and neck cancer - MSN
(MRUS) Technical Data - news.stocktradersdaily.com
Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential - Investing.com India
Merus N.V.’s SWOT analysis: promising antibody platform drives stock potential By Investing.com - Investing.com South Africa
Bicara Therapeutics Looks To Reclaim Some Of The Spotlight From Merus (NASDAQ:BCAX) - Seeking Alpha
The Netherlands: Merus raises US$300m from underwritten public offering - Investors in Healthcare
Why Merus N.V. (MRUS) Crashed On Wednesday - MSN
Merus N.V. announces proposed public offering of common shares - MSN
Merus dips 7%, prices $300M stock at $57 per share - MSN
Merus Announces Public Offering of Common Shares - TipRanks
Merus Raises $300m After ASCO Success - insights.citeline.com
Sector Update: Health Care Stocks Mixed Premarket Wednesday - marketscreener.com
Merus N V (MRUS) 財務データ
収益
当期純利益
現金流量
EPS
Merus N V (MRUS) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
大文字化:
|
ボリューム (24 時間):